Cervical cancer library

Vaccination

Featured resources

Current and Future HPV Vaccines: Promise and Challenges (2006)
PATH
This 72-page document offers an in-depth look at existing vaccines and other vaccines being developed, including therapeutic vaccines.

HPV Vaccines and Screening in the Prevention of Cervical Cancer (2006)
Bosch F, Cuzick J, Schiller J, Garnett G and Meheus A, Franco E, Wright T, eds. Vaccine. 24(S3):S1–S264.
This 250-page publication summarizes the state of the art, with contributions from over 100 authors.

Obstacles to Vaccines for AIDS, Tuberculosis, and Cervical Cancer (2006)
Khan M, Population Reference Bureau
This article outlines the potential impact of vaccines for AIDS, tuberculosis, and cervical cancer, the vaccine development process, and challenges in vaccine research and development.

Outlook. Preventing cervical cancer: Unprecedented opportunities for improving women's health
Castilaw D, Wittet S. Outlook. 2007;23(1). PATH.
This 12-page issue of Outlook provides the latest evidence-based information about cervical cancer prevention. It summarizes key issues related to HPV transmission, new HPV vaccines, and strategies for introduction in low-resource countries. This issue also identifies new methods for early detection and treatment of cervical cancer.

PATH cervical cancer vaccine project update (2007)
PATH

This four-page fact sheet provides a project summary and update of PATH's pilot introduction of HPV vaccines in India, Peru, Uganda, and Vietnam.

Preparing for the introduction of HPV vaccines: policy and programme guidance for countries (2006)
World Health Organization (WHO)
This 25-page publication is based on a UNFPA/WHO Technical Consultation on HPV Vaccines and Sexual and Reproductive Health Programs, held in March 2006 in Montreux, Switzerland. It is intended to alert a broad array of stakeholders—in sexual and reproductive health, immunization, child and adolescent health, and cancer control programs—to some of the key issues surrounding the upcoming introduction of HPV vaccines against cervical cancer.

Preventing Cervical Cancer and Other Human Papillomavirus-Related Diseases: Recent Advances in Prophylactic Vaccination (2006)
Villa L, ed. Vaccine. 24(S1)S1–S32.
This issue of Vaccine includes three articles addressing HPV’s epidemiology, immune responses to HPV, and prophylactic HPV vaccines.

Vaccine Resource Library
PATH
PATH’s Vaccine Resource Library offers a wide variety of high-quality, scientifically accurate documents and links on vaccine-preventable diseases and topics in immunization.

WHO/ICO Information Centre on HPV and Cervical Cancer
WHO and the Institut Català d’Oncologia
This website offers country-specific reports on cervical cancer burden of disease, prevalence of HPV infections, and related factors for cervical disease to evaluate prevention strategies.

General vaccination resources

A Long and Winding Road: Getting the HPV Vaccine to Women in the Developing World (2007)
Cohen, SA. Guttmacher Policy Review. 2007;10(3):15–19.
This five-page article outlines key issues affecting HPV vaccine accessibity for women in developing countries.

CERVARIX™, GlaxoSmithKline’s cervical cancer vaccine candidate induced a higher immune response in 10–14 year-old girls versus 15–25 year-old young women (2006)
This study demonstrated that CervarixTM, GlaxoSmithKline’s cervical cancer vaccine induced antibody levels against the two most common cancer-causing HPV types (HPV 16/18) at least two-fold higher in 10 to 14 year-old adolescent girls than in women 15 to 25 years-old.

Ensuring access to HPV vaccines through integrated services: a reproductive health perspective
Pollack AE, Balkin M, Edouard L, Cutts F and Broutet N on behalf of the WHO/United Nations Population Fund Working Group on Sexual and Reproductive Health and HPV Vaccines. Bulletin of the World Health Organization. 2007;85:57–63.
This seven-page article describes avenues for service delivery of HPV vaccines and critical information gaps that must be bridged in order to inform future sexual and reproductive health programming.

Fresh from the Pipeline: Quadrivalent human papillo-mavirus recombinant vaccine (2006)
Crum C, Jones C, Kirkpatrick P. Nature Reviews Drug Discovery 5:629–630.
In June 2006, a quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine (Gardasil; Merck) was approved by the US Food and Drug Administration for the prevention of several diseases, including cervical cancer, that are caused by these types of human papillomavirus. This article outlines the basis of discovery, vaccine properties, clinical data, indications, and analysis of HPV vaccine.

GARDASIL® quadrivalent HPV vaccine
Merck & Co., Inc.
Merck’s site is intended for both healthcare professionals and patients.

Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines (2006)
World Health Organization (WHO) Expert Committee on Biological Standardization
This 66-page technical publication outlines recommendations for manufacturing, clinical and nonclinical evaluation, and regulatory guidelines for recombinant HPV virus-like particle vaccines.

HPV vaccine page
US Centers for Disease Control and Prevention, National Immunization Program
Designed for both patients and healthcare professionals, the US Centers for Disease Control and Prevention's page offers overviews of HPV, cervical cancer, and the vaccine, as well as recommendations for the use of quadrivalent HPV vaccine and information about the Vaccines for Children program.

HPV Watch
AIDS Vaccine Advocacy Coalition
HPV Watch houses a range of information, publications, guidance documents, and media stories on vaccines that prevent cervical cancer.

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (2007)
US Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report Early Release. 2007; 56:1–26
This page outlines the recommendations of the Advisory Committee on Immunization Practices for the use of quadrivalent HPV vaccine.

WHO: working to ensure global quality, safety and standards in immunization
WHO
This 20-page document outlines WHO's work in the development of regulatory capacity to ensure the safety, quality and quality and efficacy of vaccines in developing countries.